Results 11 to 20 of about 7,548 (263)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population [PDF]

Journal of Diabetes Investigation, 2022
We report the findings of a single‐dose, randomized, three‐period cross‐over, clinical trial in healthy Chinese individuals (n = 24) comparing the pharmacokinetics of insulin degludec/liraglutide (IDegLira) with its individual components. Furthermore, we
Hongzhong Liu, Bin Luo, Xia Chen, Steen H. Ingwersen, Ting Jia, Lisbeth Vestergård Jacobsen, Pei Hu   +6 more
doaj   +2 more sources

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience

Indian Journal of Endocrinology and Metabolism, 2016
This study aimed to document the utility and safety of insulin degludec (IDeg) and insulin degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast.
Sanjay Kalra
doaj   +3 more sources

Insulin degludec in pregestational diabetes: evidence and perspectives [PDF]

Archives of Medical Science: Atherosclerotic Diseases
Pregestational diabetes is described when a woman with diabetes before the onset of pregnancy becomes pregnant and consequently she is vulnerable to higher risk for adverse outcomes in the embryo/foetus.
Georgios S. Papaetis, Konstantinos C. Mikellidis   +1 more
doaj   +2 more sources

Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia. [PDF]

Malays Fam Physician, 2023
Chan SP, Mumtaz M, Ratnasingam J, Tan ATB, Lim SC, Rosman A, Chee KH, Lim SK, Yew SS, Mohd Yusof BN, Lau BK, Kassim SB, Mohamed M.   +12 more
europepmc   +2 more sources

Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine [PDF]

Journal of Primary Care & Community Health
Introduction: Basal and intermediate insulin is available as U-100 (glargine, determir, NPH) or ultra-long-acting (ULA) U-200 (degludec) or U-300 (glargine).
Natalie Rosario, Cami Hunger, Allison Pettijohn, K’bria Whaley, Andrea Pabon, Valeria Hohl, Bernadette Asias-Dinh, Jodie Gee, Joshua Wollen   +8 more
doaj   +2 more sources

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

Diabetes, Metabolic Syndrome and Obesity, 2012
Fei Wang,1 Justine Surh,1 Manmeet Kaur21University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, 2Joslin Diabetes Center Affiliate, Hospital of Central Connecticut, New Britain, CT, USABackground: Insulin degludec (IDeg) is ...
Wang F, Surh J, Kaur M
doaj   +1 more source

One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

Metabolism Open, 2022
Objective: This post-authorization safety study (PASS) was conducted to evaluate the long-term safety and effectiveness of insulin degludec in patients with diabetes mellitus (DM) requiring insulin therapy in routine clinical practice in India.
Jothydev Kesavadev, L.Sreenivasa Murthy, Tirthankar Chaudhury, Sadasiva Rao Yalamanchi, J. Giri, Sunil Gupta, Sanjeev Phatak, K.D. Modi, Sanjay Chatterjee, Aparna Manjunath, Manjunatha Revanna, Arpandev Bhattacharya   +11 more
doaj   +1 more source

Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes. [PDF]

Diabetol Metab Syndr
Dogan Çakır S, Deniz Yücel H, Akgül Kızılçay Z, Adaş M.   +3 more
europepmc   +3 more sources

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials

Journal of Diabetes Investigation, 2021
Aims/Introduction To assess efficacy and safety of insulin degludec/liraglutide (IDegLira) in Japanese participants with type 2 diabetes across different baseline characteristics. Materials and Methods Data from two randomized controlled trials were used:
Mitsuhisa Komatsu, Hirotaka Watada, Shizuka Kaneko, Bue F Ross Agner, Tomoyuki Nishida, Kohei Kaku   +5 more
doaj   +1 more source

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks. DUAL VIII, a randomized trial designed to resemble clinical practice [PDF]

, 2020
This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N =
Aroda, V. R., Bardtrum, L., Dagdelen, S., Halladin, N., Haluzik, M., Orsy, P., Rodriguez, M., Sesti, G.   +7 more
core   +1 more source